The company reports an “unprecedented” 100% PSA50 rate with JANX007, but in a small, selected number of patients.

Amid a KRAS data dump, a doublet of RMC-6236 and RMC-6291 was a highlight.

Autolous, Syndax, Jazz and Shorla get US approvals in a quiet month.

Myelofibrosis projects and Merck's ROR1 ADC fight for attention at this month's conference.

Party season approaches; but first, conferences.